Signal mining study of severe cutaneous adverse events of valaciclovir or acyclovir based on the FAERS database

References

• Tempark T, John S, Rerknimitr P, et al. Drug-induced severe cutaneous adverse reactions: insights into clinical presentation, immunopathogenesis, diagnostic methods, treatment, and pharmacogenomics. Front Pharmacol. 2022;13:832048. doi: 10.3389/fphar.2022.832048
   PubMed Web of Science ®Google Scholar
• Oh HL, Kang DY, Kang HR, et al. Severe cutaneous adverse reactions in Korean pediatric patients: a study from the Korea SCAR registry. Allergy Asthma Immunol Res. 2019 Mar;11(2):241–253. doi: 10.4168/aair.2019.11.2.241
   PubMed Web of Science ®Google Scholar
• Rojas Mejía DV, Zwiener RD, Cardona Villa R, et al. Severe cutaneous adverse reactions to drugs in latin America: the RACGRAD study. J Investig Allergol Clin Immunol. 2021 Jul 26;31(4):322–331. doi: 10.18176/jiaci.0497
   PubMed Web of Science ®Google Scholar
• Owen CE, Jones JM. Recognition and management of severe cutaneous adverse drug reactions (including drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis). Med Clin North Am. 2021 Jul;105(4):577–597. doi: 10.1016/j.mcna.2021.04.001
   PubMed Web of Science ®Google Scholar
• Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. Drug Saf. 2019 Aug;42(8):973–992. doi: 10.1007/s40264-019-00825-2
   PubMed Web of Science ®Google Scholar
• Yu RJ, Krantz MS, Phillips EJ, et al. Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS). J Allergy Clin Immunol Pract. 2021 Feb;9(2):819–829.e2. doi: 10.1016/j.jaip.2020.09.021
   PubMed Web of Science ®Google Scholar
• Lonati D, Zancan A, Pasi A, et al. SJS/TEN overlap associated with lomefloxacin: case report and molecular typing studies. Dermatology. 2014;229(4):319–323. doi: 10.1159/000365188
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, StevensJohnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–96. doi: 10.1001/archderm.1993.01680220104023
   PubMedGoogle Scholar
• Verma R, Vasudevan B, Pragasam VJMJAFI. Severe cutaneous adverse drug reactions. Medical Journal Armed Forces India. 2013;69(4):375–383. doi: 10.1016/j.mjafi.2013.01.007
   PubMedGoogle Scholar
• Summary Safety Review - Valacyclovir-containing Products - Assessing the Potential Risk of Drug Reaction with Eosinophilia and Systemic Symptoms. HealCanada Web. 2022 https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&linkID=SSR00284
   Google Scholar
• SUBEESH V, MAHESWARI E, SINGH H, et al. Novel adverse events of Iloperidone: a disproportionality analysis in US Food and drug administration adverse event reporting system (FAERS) database. Curr Drug Saf. 2019;14(1):21–26. doi: 10.2174/1574886313666181026100000
   PubMed Web of Science ®Google Scholar
• ZHAO M, LI J, ZHANG J, et al. Real-world study of Lenvatinib-related colitis based on FAERS database. Chin J Mod Appl Pharm. 2023;40(3):394–398.
   Google Scholar
• HU Y, GONG J, ZHANG L, et al. Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int Immunopharmacol. 2020 Jul;84:106601.
   PubMed Web of Science ®Google Scholar
• Shu Y, Ding Y, Dai B, et al. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. Exp Opin Drug Saf. 2022;21(4):563–572. doi: 10.1080/14740338.2022.2016696
   PubMed Web of Science ®Google Scholar
• SAKAEDA T, TAMON A, KADOYAMA K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803. doi: 10.7150/ijms.6048
   PubMed Web of Science ®Google Scholar
• Fu ZR, Zhu Y, Wang XL, et al. Real-world study of adverse reactions of nusinersen based upon openFDA. Chin J Hosp Pharm. 2021;41(16):1665–1669.
   Google Scholar
• SONG Y, XU YL, LIN Y, et al. Fractures due to aromatase inhibitor Therapy for breast cancer: a real-world analysis of FAERS data in the past 15 years. Oncol Res Treat. 2020;43(3):96–102. doi: 10.1159/000505376
   PubMed Web of Science ®Google Scholar
• SHU Y, DING Y, DAI B, et al. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. Expert Opinion On Drug Safety. 2022;2021(4):1–10. doi: 10.1080/14740338.2022.2016696
   Google Scholar
• Shu Y, He X, Wu P, et al. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022 Oct 20;10:996179. doi: 10.3389/fpubh.2022.996179
   PubMed Web of Science ®Google Scholar
• Wei C, Zhang J, Yin W, et al. A real-world pharmacovigilance study of severe cutaneous adverse reactions associated with antiepileptic drug combination therapy: data mining of FDA adverse event reporting system. Expert Opin Drug Saf. 2015 Nov;22(6):1–7. doi: 10.1080/14740338.2023.2147506
   Google Scholar
• Kitayama S, Makino T, Kataoka K, et al. Valacyclovir-induced drug reaction with eosinophilia and systemic symptoms. Eur J Dermatol. 2022 Jul 1;32(4):538–539.
   PubMed Web of Science ®Google Scholar
• Sen SS, Sil A, Chakraborty U, et al. Stevens-Johnson syndrome-toxic epidermal necrolysis: a fatal cutaneous adverse reaction to oral acyclovir. BMJ Case Rep. 2020 Aug 26;13(8):e238555. doi: 10.1136/bcr-2020-238555
   PubMedGoogle Scholar
• Ojo DE, Tiab F, Walden D, et al. A peculiar case of idiopathic herpes-zoster-like Stevens-Johnson syndrome (SJS). Cureus. 2023 Mar 15;15(3):e36190. doi: 10.7759/cureus.36190
   PubMed Web of Science ®Google Scholar
• Duong TA, Valeyrie-Allanore L, Wolkenstein P, et al. Severe cutaneous adverse reactions to drugs. Lancet. 2017 Oct 28;390(10106):1996–2011. doi: 10.1016/S0140-6736(16)30378-6
   PubMed Web of Science ®Google Scholar
• Adler NR, Aung AK, Ergen EN, et al. Recent advances in the understanding of severe cutaneous adverse reactions. Br J Dermatol. 2017 Nov;177(5):1234–1247. doi: 10.1111/bjd.15423
   PubMed Web of Science ®Google Scholar
• Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600–1608. doi: 10.1056/NEJM199512143332404
   PubMed Web of Science ®Google Scholar
• Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123(2):e297–304. doi: 10.1542/peds.2008-1923
   PubMed Web of Science ®Google Scholar
• Raucci U, Rossi R, Da Cas R, et al. Italian multicenter study group for vaccine safety in drug and children. Stevens-Johnson syndrome associated with drugs and vaccines in children: a case control study. PLoS One. 2013;8(7):e68231. doi: 10.1371/journal.pone.0068231
   PubMed Web of Science ®Google Scholar